Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry

Table 6 Adverse events of interest (preferred terms; malignancies in ≥2 patients, serious infections in ≥2 patients, Herpes Zoster, tuberculosis and opportunistic infections)

	IFX (N = 890)				GLM (N = 530)				GLM-IV (N = 157)
	N of Events	N of Patients	% of Patients	Rate/100 Pt-Yrs	N of Events	N of Patients	% of Patients	Rate/100 Pt-Yrs	N of Events	N of Patients	% of Patients	Rate/100 Pt-Yrs
Malignancies
Acrochordon	2	2	0.2%	0.07	0	0	0	0	0	0	0	0
Basal cell carcinoma	2	1	0.1%	0.07	2	2	0.4%	0.19	0	0	0	0
Breast cancer	5	5	0.6%	0.17	2	2	0.4%	0.19	0	0	0	0
Leukemia	0	0	0	0	3	2	0.4%	0.28	0	0	0	0
Lung adenocarcinoma	1	1	0.1%	0.03	2	2	0.4%	0.19	0	0	0	0
Lymphoma	2	2	0.2%	0.07	0	0	0	0	0	0	0	0
Non-Hodgkin’s lymphoma	2	2	0.2%	0.07	0	0	0	0	0	0	0	0
Renal cell carcinoma	2	2	0.2%	0.07	0	0	0	0	0	0	0	0
Squamous cell carcinoma	4	4	0.4%	0.14	0	0	0	0	0	0	0	0
Uterine cancer	2	2	0.2%	0.07	1	1	0.2%	0.09	0	0	0	0
Serious infections
Arthritis bacterial	4	3	0.3%	0.14	2	2	0.4%	0.19	0	0	0	0
Cellulitis	6	6	0.7%	0.21	1	1	0.2%	0.09	0	0	0	0
Pneumonia	23	19	2.1%	0.80	5	5	0.9%	0.46	1	1	0.6%	0.39
Pyelonephritis	1	1	0.1%	0.03	3	2	0.4%	0.28	0	0	0	0
Sepsis	3	3	0.1%	0.03	0	0	0	0	0	0	0	0
Urosepsis	2	2	0.2%	0.07	1	1	0.2%	0.09	0	0	0	0
Herpes Zoster, tuberculosis and opportunistic infections
Herpes Zoster	19	19	2.1%	0.66	14	13	2.5%	1.30	1	1	0.6%	0.39
Tuberculosis (disseminated)	1	1	0.1%	0.03	0	0	0	0	0	0	0	0
Candidiasis	4	4	0.4%	0.14	0	0	0	0	0	0	0	0
Histoplasmosis	1	1	0.1%	0.03	0	0	0	0	0	0	0	0
Onychomycosis	2	2	0.2%	0.07	0	0	0	0	0	0	0	0

ISSN: 2520-1026